<DOC>
	<DOCNO>NCT01018017</DOCNO>
	<brief_summary>Randomized , placebo-controlled , parallel-group , double-blind , multiple-dose , activity safety clinical study SRT2104 administer orally daily 28 consecutive day . This inpatient/outpatient study assess safety pharmacokinetics SRT2104 type 2 diabetic male female subject exist , stable , background metformin therapy . Approximately 80 subject enrol . Subjects evenly randomize receive SRT2104 2.0 g/day placebo feed state . Subjects require stay overnight study center Days -2 , -1 , 0 , 1 ( optional discharge investigator 's discretion ) , 27 , 28 , 41 , 42 . During admission , pharmacokinetic , biomarker glycated albumin sample collect , glucose profiling , OGTT , glucose stabilization , hyperinsulinemc euglycemic clamp ( HEGC ) study indirect calorimetry various safety activity procedure perform . On Day 1 study , subject randomize receive SRT2104 placebo . Day 43 last day study subject release . In addition , subject ask return study center Day 14 interim safety assessment . During dose period , study personnel contact subject telephone Days 7 21 conduct safety assessment . Subjects require monitor fast blood glucose complete daily diary outpatient portion study Days 1 28 . A follow-up , safety phone call occur 30 day follow final dose SRT2104 placebo ( Day 58 study ) identify possible additional adverse event concomitant medication .</brief_summary>
	<brief_title>A Clinical Study Assess Safety , Tolerability , Activity Oral SRT2104 Capsules Administered 28 Days Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Randomized , placebo-controlled , parallel-group , double-blind , multiple-dose , activity safety clinical study SRT2104 administer orally daily 28 consecutive day . This inpatient/outpatient study assess safety pharmacokinetics ( PK ) SRT2104 type 2 diabetic ( T2D ) male female subject exist , stable , background metformin therapy . Approximately 112 subject age 18-65 year , fulfill inclusion/exclusion criterion , screen study enroll approximately 80 subject . Subjects evenly randomize receive SRT2104 2.0 g/day placebo approximately 15 minute follow consumption standardize morning meal . Subjects remain fixed dose test material dosing day study . Subjects sign inform consent form Screening Visit , undergo screen assessment verify eligibility study . If eligible willing participate , subject return clinic within 21 day Screening Visit participate pre-dosing phase study . On Day 1 study , subject randomize receive SRT2104 placebo . Subjects require stay overnight study center Days -2 , -1 , 0 , 1 ( optional discharge investigator 's discretion ) , 27 , 28 , 41 , 42 testing , assess safety , gather require biomarker sample . In addition , subject ask return study center Day 14 interim safety assessment . The subject telephone Days 7 21 ass safety . Subjects require monitor fast blood glucose complete daily diary outpatient portion study Days 1 28 . A follow-up , safety phone call occur 30 day follow final dose SRT2104 placebo ( Day 58 study ) identify possible additional adverse event ( AEs ) concomitant medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Able willing provide write informed consent participate study Ambulatory male female subject ( race ) T2D within age range 1865 year ( inclusive ) time screen All female subject must nonchildbearing potential . All male subject must agree partner use doublebarrier birth control abstinence participate study 12 week follow last dose investigational product . For purpose study , nonchildbearing define : Amenorrheic least 12 consecutive month ; menopausal status amenorrheic female confirm demonstrate level follicle stimulate hormone ( FSH ) &gt; 40138 mIU/mL estradiol &lt; 30 pg/mL entry . In event subject 's menopause status clearly establish ( example , subject indicate amenorrheic 10 year ) , FSH and/or estradiol level consistent postmenopausal condition , determination subject eligibility discretion principal investigator agreement independent medical monitor At least 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) post tubal ligation The subject must stable metformin monotherapy minimum 3 month prior Screening visit . HbA1c 6.5 % 9.5 % ( inclusive ) Body Mass Index ( BMI ) 2238 kg/m^2 ( inclusive ) Resting supine blood pressure ( BP ) &lt; 160/90 mmHg Have normal 12lead electrocardiogram ( ECG ) one change consider clinically insignificant medical review QTc interval define : QTcB must &lt; 450 msec male &lt; 470 msec female ( base single average QTc value triplicate ECGs obtain brief period ) QTcB must &lt; 480 msec subject Bundle Branch Block Comprehension nature purpose study able comply protocol requirement Able communicate person telephone manner allow protocol procedure carry safely reliably opinion investigative site staff Any major illness 3 month prior study entry significant ongoing chronic medical illness relate diabetes ( e.g. , recent myocardial infarction , unstable angina , stroke , transient ischemic attack ) opinion principal investigator medical monitor could risk subject safety interpretation result Renal liver impairment , define : Serum creatinine level ≥ 1.4 mg/dL female ≥ 1.5 mg/dL male AST ALT ≥ 2xULN alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Screening A positive test HIV antibody History current gastrointestinal disease influence drug absorption judge investigator Significant history alcoholism drug/chemical abuse , positive result urine drug/alcohol screen Screening Visit , consume 28 unit alcohol per week ( one unit alcohol equal 250 mL beer lager , one glass wine , 20 mL spirit ) Participation clinical trial within 3 month prior first dose investigational product current study History difficulty donate blood accessibility vein leave right arm Donation loss blood ( 500 mL ) within 3 month prior receive first dose investigational product Use prescription drug therapy , exception prescription medication administer stable dose least 6 week prior Screening , provide medication contraindicate metformin label ( see Appendix A Glucophage® Summary Product Characteristics ) Use antidiabetic therapy metformin , within 3 month first dose investigational product Use dietary herbal supplement within 3 week prior first dose investigational product History sensitivity study medication , component thereof history drug allergy , opinion investigator medical monitor , contraindicate participation Active neoplastic disease history neoplastic disease within 5 year study entry ( except basal cell carcinoma skin carcinoma situ ) Increased risk thrombosis , e.g. , subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>